Viking Therapeutics (VKTX) CCO buys 4,475 shares at $33.50

Rhea-AI Filing Summary

Viking Therapeutics, Inc. reported that Chief Commercial Officer Neil William Aubuchon purchased common stock in the company. On this transaction date, he made an open-market purchase of 4,475 shares of common stock at $33.50 per share. Following this trade, he directly holds 4,475 shares of Viking Therapeutics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aubuchon Neil William

(Last) (First) (Middle)

9920 PACIFIC HEIGHTS BLVD

SUITE 350

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Viking Therapeutics, Inc. [ VKTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.00001 per share	03/10/2026		P		4,475	A	$33.5	4,475	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Michael Morneau, as Attorney-in-Fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Viking Therapeutics (VKTX) report for Neil William Aubuchon?

Viking Therapeutics reported that Chief Commercial Officer Neil William Aubuchon completed an open-market purchase of company stock. He bought 4,475 shares of common stock, reflecting a direct increase in his personal ownership position in Viking Therapeutics.

How many Viking Therapeutics (VKTX) shares did Neil William Aubuchon buy, and at what price?

Neil William Aubuchon purchased 4,475 shares of Viking Therapeutics common stock at a price of $33.50 per share. The transaction was reported as an open-market purchase, indicating he bought the shares on the public market at that stated price.

What is Neil William Aubuchon’s role at Viking Therapeutics (VKTX) in this Form 4 filing?

Neil William Aubuchon is identified as the Chief Commercial Officer of Viking Therapeutics. The Form 4 filing links this executive role to his recently reported open-market purchase of common stock, showing increased direct equity ownership aligned with his leadership position at the company.

How many Viking Therapeutics (VKTX) shares does Neil William Aubuchon own after this transaction?

After the reported transaction, Neil William Aubuchon directly owns 4,475 shares of Viking Therapeutics common stock. The Form 4 shows this same share count as both the amount purchased in the transaction and his total direct holdings following the purchase.

Was Neil William Aubuchon’s Viking Therapeutics (VKTX) stock transaction a direct open-market purchase?

Yes. The transaction is classified as an open-market purchase of common stock and is marked as direct ownership. This means Aubuchon personally bought the shares on the open market, and they are held in his own name rather than through an intermediate entity.

Does the Form 4 for Viking Therapeutics (VKTX) show any stock sales by Neil William Aubuchon?

No stock sales are shown for Neil William Aubuchon in this Form 4. The filing reports only a single open-market purchase of 4,475 shares, with no dispositions or derivative transactions listed in the reported transaction summary.